We are live on ! Find out more
ADPT icon

Adaptive Biotechnologies

187 hedge funds and large institutions have $732M invested in Adaptive Biotechnologies in 2024 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 66 increasing their positions, 44 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 20

56% more call options, than puts

Call options by funds: $403K | Put options by funds: $259K

50% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 44

36% more capital invested

Capital invested by funds: $538M → $732M (+$194M)

6% more funds holding

Funds holding: 176187 (+11)

3.84% less ownership

Funds ownership: 100.88%97.04% (-3.8%)

Holders
187
Holders Change
+11
Holders Change %
+6.25%
% of All Funds
2.69%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
32
Increased
66
Reduced
44
Closed
20
Calls
$403K
Puts
$259K
Net Calls
+$144K
Net Calls Change
+$379K
Name Holding Trade Value Shares
Change
Change in
Stake
Viking Global Investors
1
Viking Global Investors
Connecticut
$154M
RCMNY
2
Rubric Capital Management (New York)
New York
$73.7M +$1.74M +400,000 +3%
BlackRock
3
BlackRock
New York
$61.1M +$1.17M +268,839 +2%
AIM
4
ARK Investment Management
Florida
$59.4M +$824K +189,134 +2%
Vanguard Group
5
Vanguard Group
Pennsylvania
$54.5M +$1.8M +412,529 +4%
Millennium Management
6
Millennium Management
New York
$48.1M +$602K +138,232 +1%
Sumitomo Mitsui Trust Group
7
Sumitomo Mitsui Trust Group
Japan
$39.6M +$3.63M +834,253 +12%
NAMA
8
Nikko Asset Management Americas
New York
$39.5M +$3.55M +814,106 +12%
AAP
9
Aristotle Atlantic Partners
Florida
$15.4M +$118K +27,013 +0.9%
Massachusetts Financial Services
10
Massachusetts Financial Services
Massachusetts
$14.8M -$4.49M -1,030,663 -26%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$13.6M -$89.1K -20,450 -0.8%
State Street
12
State Street
Massachusetts
$13.1M +$213K +48,885 +2%
BWLSA
13
Blue Water Life Science Advisors
California
$11M +$9.35M +2,145,145 New
Goldman Sachs
14
Goldman Sachs
New York
$8.96M +$3.05M +701,135 +67%
Dimensional Fund Advisors
15
Dimensional Fund Advisors
Texas
$7.27M +$226K +51,898 +4%
PC
16
Pier Capital
Connecticut
$6.53M +$961K +220,586 +21%
Pictet Asset Management
17
Pictet Asset Management
Switzerland
$6.51M -$1.66M -380,222 -23%
SCM
18
Soleus Capital Management
Connecticut
$5.7M -$2.65M -607,251 -35%
Morgan Stanley
19
Morgan Stanley
New York
$5.37M +$2.32M +531,672 +103%
Aberdeen Group
20
Aberdeen Group
United Kingdom
$5.27M
Northern Trust
21
Northern Trust
Illinois
$4.93M +$155K +35,651 +4%
Charles Schwab
22
Charles Schwab
California
$4.69M +$44.7K +10,262 +1%
JP Morgan Chase
23
JP Morgan Chase
New York
$4.55M -$64.2K -14,724 -2%
Bank of America
24
Bank of America
North Carolina
$3.99M -$1.58M -362,073 -32%
DP
25
DDD Partners
Washington
$3.94M -$3.62K -831 -0.1%

ADPT Hedge Fund Activity: Q3 2024 in Review

187 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q3 2024, worth a combined $732M — up 36% from $538M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new ADPT positions and 20 closed out — a net gain of 12 holders — while 66 added to existing stakes and 44 trimmed.

The largest buyer was Blue Water Life Science Advisors, opening a new position worth an estimated $9.35M. The largest seller was Matrix Capital Management Company, cutting an estimated $47.6M.

  • 187 institutional investors held Adaptive Biotechnologies (ADPT) as of Q3 2024, up from 176 in Q2 2024.
  • Funds reported $732M of Adaptive Biotechnologies stock for Q3 2024, up 36% quarter-over-quarter.
  • 32 funds opened new Adaptive Biotechnologies positions in Q3 2024 and 20 closed out, a net change of +12 holders.
  • The largest Adaptive Biotechnologies buyer in Q3 2024 was Blue Water Life Science Advisors, an estimated $9.35M added.
  • The largest Adaptive Biotechnologies seller in Q3 2024 was Matrix Capital Management Company, an estimated $47.6M sold.

Based on aggregated 13F filings for Q3 2024.